Search Results
582 Results Found for “lung cancer”
Metastatic triple-negative breast cancer (mTNBC) is a clinically heterogeneous disease, but compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is generally associated with a poorer prognosis and has historically had limited therapeutic options.1 The 5-year survival rate remains ...
Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment
This article examines current evidence supporting the use of neoadjuvant immunotherapy in patients with resectable macroscopic stage III melanoma and critically discusses the selection of appropriate adjuvant therapy following surgery. It is written in the context of emerging evidence from ...
As EORTC enters a new chapter under the Presidency of Professor Benjamin Besse (Gustave Roussy Institute and Paris-Saclay University, Villejuif, France), the organization is looking to accelerate academic research while keeping patients and scientific independence at its core. In this detailed and in-depth Q&A, Prof Besse shares his priorities for EORTC, from supporting the next generation of investigators and broadening clinical trial populations, to giving greater weight to quality of life and patient perspectives. He also considers how emerging technologies, including artificial intelligence, could reshape the way cancer research is conducted.
Dr Igor Gómez-Randulfe RodrÃguez examines four studies from WCLC 2026 that could influence the evolving management of small-cell lung cancer and molecularly defined non-small-cell lung cancer, from B7-H3 antibody-drug conjugates and MRI surveillance to emerging therapies targeting EGFR exon 20 insertions and ROS1.
The 2026 World Conference on Lung Cancer delivered several results with the potential to change clinical practice. My main takeaway was the speed at which effective options are multiplying in both small-cell lung cancer and molecularly defined non-small-cell lung cancer. The immediate advance is welcome, but it also makes treatment selection more complex: mature survival, intracranial control, toxicity, sequencing and access will increasingly matter as much as response rate or progression-free survival.
Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...
ASCO 2026 showed that thoracic oncology is moving beyond promising signals and increasingly closer to practice-changing evidence across multiple fields — from bispecific antibodies and ADC-based combinations to targeted therapy in both metastatic and peri-operative settings. In this piece, Dr Federico Monaca breaks down eight major abstracts from ASCO26, highlighting their take-aways and considering their potential relevance for clinical practice.
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1Â Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
See who the oncology community selected as the rising stars of 2026!
As part of our touchONCOLOGY Future Leaders 2026 programme, Dr Federico Monaca reflects on the mentors who shaped his approach to research and clinical trials, the importance of patience and patient-centred care, and the transformative potential of next-generation immunotherapies.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
